PPARGC1A and Obesity: Obesity was associated with an increase in heart weight as compared to mice treated with the EET-agonist alone (0.16 ± 0.004 vs. 0.13 ± 0.001, respectively), while the EET-agonist in combination with decreased levels of PGC-1α prevented the beneficial effect of EET-agonist on heart weight (0.14 ± 0.006) (Table 1).